Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF Warfarin Versus NOACs Versus LAA Closure

Journal of the American College of Cardiology

Volumn 66, Issue 24, 2015, Pages 2728-2739

  Reddy, Vivek Y ^a   Akehurst, Ronald L ^b   Armstrong, Shannon O ^c   Amorosi, Stacey L ^d   Beard, Stephen M ^e   Holmes, David R ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c GfK Bridgehead   (United States)

^d BOSTON SCIENTIFIC CORPORATION   (United States)

^e BRESMED   (United Kingdom)

^f MAYO CLINIC   (United States)

Author keywords

apixaban; dabigatran; edoxaban; quality of life; rivaroxaban; Watchman

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ATRIAL FIBRILLATION; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; FORECASTING; HEALTH CARE COST; HEART ATRIUM APPENDAGE; HEART SURGERY; MASSACHUSETTS; PRACTICE GUIDELINE; PROCEDURES; STROKE; TIME FACTOR;

ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; FORECASTING; HEALTH CARE COSTS; MASSACHUSETTS; PRACTICE GUIDELINES AS TOPIC; STROKE; TIME FACTORS; WARFARIN;

EID: 84959440192     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.09.084     Document Type: Article

References (52)

1. A.S. Go, D. Mozaffarian, V.L. Roger, and et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association Circulation 127 2013 e6 e245
2. W.C. Lee, G.A. Lamas, S. Balu, and et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective J Med Econ 11 2008 281 298
3. K.S. Coyne, C. Paramore, S. Grandy, and et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States Value Health 9 2006 348 356
4. C.T. Ruff, R.P. Giugliano, E. Braunwald, and et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials Lancet 383 2014 955 962
5. D.R. Holmes, V.Y. Reddy, Z.G. Turi, and et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial Lancet 374 2009 534 542
6. V.Y. Reddy, H. Sievert, J. Halperin, and et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial JAMA 312 2014 1988 1998
7. D. Coyle, K. Coyle, C. Cameron, and et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation Value Health 16 2013 498 506
8. A.R. Harrington, E.P. Armstrong, P.E. Nolan Jr., and et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Stroke 44 2013 1676 1681
9. J.H.S. You Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation: a cost-effectiveness analysis J Gen Intern Med 29 2014 438 446
10. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
11. R. Pisters, D.A. Lane, R. Nieuwlaat, and et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
12. S.J. Connelly, M.D. Ezekowitz, S. Yusuf, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
13. C.B. Granger, J.H. Alexander, J.J.V. McMurray, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
14. ACTIVE Investigators Effects of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
15. ACTIVE Writing Group of the ACTIVE Investigators Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
16. M.D. Ezekowitz, S.L. Bridgers, K.E. James, and et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation N Engl J Med 327 1992 1406 1412
17. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation N Engl J Med 323 1990 1505 1511
18. S.J. Connelly, A. Laupaucis, M. Gent, and et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study J Am Coll Cardiol 18 1991 349 355
19. Stroke Prevention in Atrial Fibrillation investigators Stroke Prevention in Atrial Fibrillation study: final results Circulation 84 1991 527 539
20. P. Petersen, G. Boysen, J. Godtfredsen, and et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study Lancet 8631 1989 175 178
21. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
22. R.P. Giugliano, C.T. Ruff, E. Braunwald, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
23. HCUP Databases. Healthcare Cost and Utilization Project (HCUP) Overview of the National (Nationwide) Inpatient Sample May 2015 Agency for Heathcare Research and Quality Rockville, MD Available at: www.hcup-us.ahrq.gov/nisoverview.jsp Accessed October 4, 2015
24. Social Security Administration. Actuarial Life Table 2011. Available at: http://www.ssa.gov/oact/STATS/table4c6.html. Accessed October 4, 2015.
25. M.S. Dennis, J.P.S. Burn, P.A.G. Sandercock, and et al. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project Stroke 24 1993 796 800
26. G.Y.H. Lip, R. Nieuwlaat, R. Pisters, and et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation Chest 137 2010 263 272
27. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
28. M.J. Ariesen, S.P. Claus, G.J.E. Rinkel, and et al. Risk factors for intracerebral hemorrhage in the general population Stroke 34 2003 2060 2065
29. C.L. O'Brien, and B.F. Gage Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation JAMA 293 2005 699 706
30. S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 123 2011 2562 2570
31. B.F. Gage, A.B. Cardinalli, G.W. Albers, and et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation JAMA 274 1995 1839 1845
32. S. Lee, M.W. Anglade, D. Pham, and et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation Am J Cardiol 110 2012 845 851
33. M.B. Nichol, N. Sengupta, and D.R. Globe Evaluating quality-adjusted life years: estimation of the health utility index (HU12) from the SF-36 Med Decis Making 21 2001 105 112
34. O. Alli, S. Doshi, S. Kar, and et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation J Am Coll Cardiol 61 2013 1790 1798
35. D.G. Fryback, N.C. Dunham, M. Palta, and et al. U.S. norms for six generic health-related quality of life indexes from the National Health Measurement study Med Care 45 2007 1162 1170
36. P.W. Sullivan, T.W. Arant, S.L. Ellis, and et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US Pharmacoeconomics 24 2006 1021 1033
37. M.C. Weinstein, J.E. Siegel, M.R. Gold, and et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine JAMA 276 1996 1253 1258
38. Centers for Medicare & Medicaid Services. Acute Inpatient PPS FY 2015 Final Rule Tables. 2014. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2015-IPPS-Final-Rule-Home-Page-Items/FY2015-Final-Rule-Tables.html. Accessed October 4, 2015.
39. Centers for Medicare & Medicaid Services. Inpatient Rehabilitation Facility PPS Data Files. 2014. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/InpatientRehabFacPPS/Data-Files.html. Accessed October 4, 2015.
40. L.E. Cipriano, M.L. Steinberg, G.S. Gazelle, and et al. Comparing and predicting the costs and outcomes of patients with major and minor stroke using the Boston Acute Stroke Imaging Scale neuroimaging classification system AJNR Am J Neuroradiol 30 2009 703 709
41. C.J. Mercaldi, K. Sui, S.D. Sander, and et al. Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fibrillation Cardiol Res Pract 2012 2012 645469
42. J.J. Caro, and K.F. Huybrechts Stroke treatment economic model (STEM): predicting long-term costs from functional status Stroke 30 1999 2574 2579
43. Centers for Medicare & Medicaid Services. Acute IPPS FY 2016 Final Rule and Correction Notice Tables. 2015. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page-Items/FY2016-IPPS-Final-Rule-Tables.html. Accessed October 4, 2015.
44. The Coding Institute. Available at: http://www.codinginstitute.com/supercoder. Accessed October 5, 2015.
45. DMD America. AnalysourceBiweekly.com. Available at: https://www.analysource.com/pricing.html. Accessed October 5, 2015.
46. A.H. Briggs, M.C. Weinstein, E.A.L. Fenwick, and et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 Value Health 15 2012 835 842
47. N.A. Solomon, H.A. Glick, C.J. Russo, and et al. Patient preferences for stroke outcomes Stroke 25 1994 1721 1725
48. K. Lang, D. Bozkaya, A.A. Patel, and et al. Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis BMC Health Serv Res 14 2014 329
49. J.F. Meschia, C. Bushnell, B. Boden-Albala, and et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke 45 2014 3754 3832
50. V.W. Lee, B. Yan, I. Chow, and et al. Cost-effectiveness of left atrial appendage occlusion device compared with 7 oral anticoagulants for stroke prevention in atrial fibrillation (abstr) J Am Coll Cardiol 64 2014
51. S.M. Singh, A. Micieli, and H.C. Wijeysundera An economic evaluation of percutaneous left atrial appendage occlusion: dabigatran and warfarin for stroke prevention in patients with non-valvular atrial fibrillation Circulation 127 2013 2414 2423
52. J.P. Jansen, R. Fleurence, B. Devine, and et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 Value Health 14 2011 417 428